Evidence map›Paper›PMID 24752434›Full record

ArticleHypertension (Dallas, Tex. : 1979)2014

Decreased level of cord blood circulating endothelial colony-forming cells in preeclampsia.

Rocio Muñoz-Hernandez, Maria L Miranda, Pablo Stiefel, Ruei-Zeng Lin, Juan M Praena-Fernández, Maria J Dominguez-Simeon, Jose Villar, Rafael Moreno-Luna, Juan M Melero-Martin

Abstract read
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Endothelial Progenitor Cells in Life, Pregnancy and Disease.Expert reviews in molecular medicine · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Pathological Roles for Endothelial Colony-Forming Cells in Neonatal and Adult Lung Disease.American journal of respiratory cell and molecular biology · 2023
    Review
  11. Human Endothelial Colony-Forming Cells.Cold Spring Harbor perspectives in medicine · 2022
    Article
  12. Coronary Artery Restenosis in Women by History of Preeclampsia.Journal of the American Heart Association · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Rocio Muñoz-HernandezFrom the CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV) (R.M.-H., M.L.M., P.S., M.J.D.-S., J.V., R.M.-L.) and Unidad de Asesoría Estadística, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) (J.M.P.-F.), Instituto de Biomedicina de Sevilla (IBiS) and Hospital Universitario Virgen del Rocío, Seville, Spain; Department of Cardiac Surgery, Boston Children's Hospital, MA (R.M.-H., R.-Z.L., R.M.-L., J.M.M.-M.); Department of Surgery, Harvard Medical School, Boston, MA (R.-Z.L., R.M.-L., J.M.M.-M.); and Harvard Stem Cell Institute, Cambridge, MA (J.M.M.-M.).
Maria L MirandaFrom the CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV) (R.M.-H., M.L.M., P.S., M.J.D.-S., J.V., R.M.-L.) and Unidad de Asesoría Estadística, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) (J.M.P.-F.), Instituto de Biomedicina de Sevilla (IBiS) and Hospital Universitario Virgen del Rocío, Seville, Spain; Department of Cardiac Surgery, Boston Children's Hospital, MA (R.M.-H., R.-Z.L., R.M.-L., J.M.M.-M.); Department of Surgery, Harvard Medical School, Boston, MA (R.-Z.L., R.M.-L., J.M.M.-M.); and Harvard Stem Cell Institute, Cambridge, MA (J.M.M.-M.).
Pablo StiefelFrom the CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV) (R.M.-H., M.L.M., P.S., M.J.D.-S., J.V., R.M.-L.) and Unidad de Asesoría Estadística, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) (J.M.P.-F.), Instituto de Biomedicina de Sevilla (IBiS) and Hospital Universitario Virgen del Rocío, Seville, Spain; Department of Cardiac Surgery, Boston Children's Hospital, MA (R.M.-H., R.-Z.L., R.M.-L., J.M.M.-M.); Department of Surgery, Harvard Medical School, Boston, MA (R.-Z.L., R.M.-L., J.M.M.-M.); and Harvard Stem Cell Institute, Cambridge, MA (J.M.M.-M.).
Ruei-Zeng LinFrom the CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV) (R.M.-H., M.L.M., P.S., M.J.D.-S., J.V., R.M.-L.) and Unidad de Asesoría Estadística, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) (J.M.P.-F.), Instituto de Biomedicina de Sevilla (IBiS) and Hospital Universitario Virgen del Rocío, Seville, Spain; Department of Cardiac Surgery, Boston Children's Hospital, MA (R.M.-H., R.-Z.L., R.M.-L., J.M.M.-M.); Department of Surgery, Harvard Medical School, Boston, MA (R.-Z.L., R.M.-L., J.M.M.-M.); and Harvard Stem Cell Institute, Cambridge, MA (J.M.M.-M.).
Juan M Praena-FernándezFrom the CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV) (R.M.-H., M.L.M., P.S., M.J.D.-S., J.V., R.M.-L.) and Unidad de Asesoría Estadística, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) (J.M.P.-F.), Instituto de Biomedicina de Sevilla (IBiS) and Hospital Universitario Virgen del Rocío, Seville, Spain; Department of Cardiac Surgery, Boston Children's Hospital, MA (R.M.-H., R.-Z.L., R.M.-L., J.M.M.-M.); Department of Surgery, Harvard Medical School, Boston, MA (R.-Z.L., R.M.-L., J.M.M.-M.); and Harvard Stem Cell Institute, Cambridge, MA (J.M.M.-M.).
Maria J Dominguez-SimeonFrom the CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV) (R.M.-H., M.L.M., P.S., M.J.D.-S., J.V., R.M.-L.) and Unidad de Asesoría Estadística, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) (J.M.P.-F.), Instituto de Biomedicina de Sevilla (IBiS) and Hospital Universitario Virgen del Rocío, Seville, Spain; Department of Cardiac Surgery, Boston Children's Hospital, MA (R.M.-H., R.-Z.L., R.M.-L., J.M.M.-M.); Department of Surgery, Harvard Medical School, Boston, MA (R.-Z.L., R.M.-L., J.M.M.-M.); and Harvard Stem Cell Institute, Cambridge, MA (J.M.M.-M.).
Jose VillarFrom the CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV) (R.M.-H., M.L.M., P.S., M.J.D.-S., J.V., R.M.-L.) and Unidad de Asesoría Estadística, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) (J.M.P.-F.), Instituto de Biomedicina de Sevilla (IBiS) and Hospital Universitario Virgen del Rocío, Seville, Spain; Department of Cardiac Surgery, Boston Children's Hospital, MA (R.M.-H., R.-Z.L., R.M.-L., J.M.M.-M.); Department of Surgery, Harvard Medical School, Boston, MA (R.-Z.L., R.M.-L., J.M.M.-M.); and Harvard Stem Cell Institute, Cambridge, MA (J.M.M.-M.).
Rafael Moreno-LunaFrom the CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV) (R.M.-H., M.L.M., P.S., M.J.D.-S., J.V., R.M.-L.) and Unidad de Asesoría Estadística, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) (J.M.P.-F.), Instituto de Biomedicina de Sevilla (IBiS) and Hospital Universitario Virgen del Rocío, Seville, Spain; Department of Cardiac Surgery, Boston Children's Hospital, MA (R.M.-H., R.-Z.L., R.M.-L., J.M.M.-M.); Department of Surgery, Harvard Medical School, Boston, MA (R.-Z.L., R.M.-L., J.M.M.-M.); and Harvard Stem Cell Institute, Cambridge, MA (J.M.M.-M.).
Juan M Melero-MartinFrom the CSIC/Universidad de Sevilla, Unidad Clínico-Experimental de Riesgo Vascular (UCAMI-UCERV) (R.M.-H., M.L.M., P.S., M.J.D.-S., J.V., R.M.-L.) and Unidad de Asesoría Estadística, Metodología y Evaluación de Investigación, Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) (J.M.P.-F.), Instituto de Biomedicina de Sevilla (IBiS) and Hospital Universitario Virgen del Rocío, Seville, Spain; Department of Cardiac Surgery, Boston Children's Hospital, MA (R.M.-H., R.-Z.L., R.M.-L., J.M.M.-M.); Department of Surgery, Harvard Medical School, Boston, MA (R.-Z.L., R.M.-L., J.M.M.-M.); and Harvard Stem Cell Institute, Cambridge, MA (J.M.M.-M.). juan.meleromartin@childrens.harvard.edu rmluna@sescam.jccm.es.

Funding

Engineering vascularized tissue in vivo using postnatal progenitor cellsR00EB009096 · NIBIB · BOSTON CHILDREN'S HOSPITAL · PI MELERO-MARTIN, JUAN M · 2011 to 2013
$719k
Engineering vascularized tissue in vivo using postnatal progenitor cellsK99EB009096 · NIBIB · BOSTON CHILDREN'S HOSPITAL · PI MELERO-MARTIN, JUAN M · 2009 to 2010
$180k
NIBIB NIH HHS K99 EB009096NIBIB NIH HHS R00 EB009096NIBIB NIH HHS R00EB009096
6 · The paper itself

Abstract

Preeclampsia is a pregnancy-related disorder associated with increased cardiovascular risk for the offspring. Endothelial colony-forming cells (ECFCs) are a subset of circulating endothelial progenitor cells that participate in the formation of vasculature during development. However, the effect of preeclampsia on fetal levels of ECFCs is largely unknown. In this study, we sought to determine whether cord blood ECFC abundance and function are altered in preeclampsia. We conducted a prospective cohort study that included women with normal (n=35) and preeclamptic (n=15) pregnancies. We measured ECFC levels in the umbilical cord blood of neonates and characterized ECFC phenotype, cloning-forming ability, proliferation, and migration toward vascular endothelial growth factor-A and fibroblast growth factor-2, in vitro formation of capillary-like structures, and in vivo vasculogenic ability in immunodeficient mice. We found that the level of cord blood ECFCs was statistically lower in preeclampsia than in control pregnancies (P=0.04), a reduction that was independent of other obstetric factors. In addition, cord blood ECFCs from preeclamptic pregnancies required more time to emerge in culture than control ECFCs. However, once derived in culture, ECFC function was deemed normal and highly similar between preeclampsia and control, including the ability to form vascular networks in vivo. This study demonstrates that preeclampsia affects ECFC abundance in neonates. A reduced level of ECFCs during preeclamptic pregnancies may contribute to an increased risk of developing future cardiovascular events.

Indexed as

AdultCell MovementCell ProliferationEndothelial CellsFemaleFetal BloodFibroblast Growth Factor 2HumansPre-EclampsiaPregnancyProspective StudiesRisk FactorsStem CellsVascular Endothelial Growth Factor AFibroblast Growth Factor 2Vascular Endothelial Growth Factor Afetal bloodpreeclampsiapregnancy

Identifiers

PMID24752434
PMCPMC4057301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.